首页> 外文期刊>Human Pathology >Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap
【24h】

Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap

机译:KI-67和P53的免疫组织化学染色模式在植物反应性尿路上的尿液原位和尿路上皮癌原位上表现出显着重叠

获取原文
获取原文并翻译 | 示例
           

摘要

Flat urothelial lesions with atypia may pose significant diagnostic challenges. Given frequent increased proliferation rates in florid reactive urothelial atypia and limited studies on the interpretation of p53 stains in the urothelium (following current standard guidelines for correlation with P53 mutation status), we sought to further study the discriminatory value of Ki-67 and p53 for florid reactive urothelial atypia versus urothelial carcinoma in situ (CIS). Bladder specimens diagnosed as reactive urothelial atypia (n = 40) and CIS (n = 40) were assessed by immunohistochemical staining with antibodies for Ki-67, p53, CD44, and CK20 Immunoreactivity was scored based on percent cells positive for Ki-67 and pattern of reactivity with p53 (aberrant: diffuse strong positive or negative; normal: patchy/wild type). CD44 and CK20 reactivity patterns served as adjunctive internal validation controls for reactive urothelial atypia and CIS, as previously described. In reactive urothelial atypia, Ki-67 ranged from 0% to 90% (mean, 34% +/- 26) with 30 cases (75%) having >10%. In CIS, Ki-67 ranged from 5% to 95% (mean, 50% +/- 25) with 17 cases (43%) having >50%. In all 40 cases (100%) of reactive urothelial atypia, p53 expression had a wild-type pattern. In CIS, aberrant p53 expression was identified in 15 cases (37%): 3 cases (7%) were p53 negative (i.e. null phenotype) and 12 cases (30%) showed strong and diffuse nuclear reactivity (in >85% of cells). The remaining 25 cases (63%) of CIS had a p53 wild-type pattern of expression. Cytoplasmic CK20 immunoreactivity in umbrella cells was seen in 34 cases (85%) of reactive urothelial atypia, and 6 cases (15%) were negative. In addition, 35 cases (88%) of reactive urothelial atypia demonstrated full-thickness CD44 expression, while 5 cases (12%) had expression confined to the basal/parabasal layers of the urothelium. Strong and diffuse CK20 positivity was present in 39 cases (98%) of CIS, and patchy positivity was detected in 1 case (2%). None of the CIS cases overexpressed CD44: 16 cases (40%) showed focal expression in the nonneoplastic basal cell layer; 24 cases (60%) demonstrated no staining. In summary, Ki-67 has poor discriminatory value for reactive urothelial atypia versus CIS and adds little to the classic CK20/CD44 immunophenotype. While p53 sensitivity for CIS is relatively low (30%) and interpretation as either wild type or negative may be challenging in a small subset of cases, strong and diffuse nuclear reactivity was 100% specific in the distinction from florid reactive urothelial atypia in this cohort. (C) 2020 Elsevier Inc. All rights reserved.
机译:含有Atypia的扁平尿路上位病变可能会造成显着的诊断挑战。常常增加植物反应性尿路上的尿液中的增殖率和对尿浆中P53污渍的解释的有限研究(按照与P53突变状态相关的相关性指南),我们寻求进一步研究KI-67和P53的歧视价值植物反应性尿路上皮阿托氏菌与Ur pothelial癌原位(CIS)。通过用Ki-67,P53,CD44和CK20的抗体的免疫组织化学染色评估被诊断为反应性尿液原型(n = 40)和顺式(n = 40)的膀胱样本评分,基于Ki-67的百分比细胞呈阳性的百分比细胞进行评分与p53的反应性模式(异常:弥漫性强度或负;正常:斑驳/野生型)。如前所述,CD44和CK20反应性模式用作反应性尿路上的辅助内部验证控制,如前所述。在反应性尿路上皮原型中,KI-67的范围为0%至90%(平均,34%+/- 26),30例(75%)> 10%。在CIS中,KI-67的5%至95%(平均值,50%+/- 25),17例(43%)> 50%。在所有40例(100%)的反应性尿路上皮缺点中,P53表达具有野生型模式。在CIS中,在15例(37%)中鉴定了异常P53表达:3例(7%)为p53阴性(即零表型),12例(30%)显示出强和弥漫性核反应性(in> 85%的细胞)。剩下的25例(63%)的CIS具有P53野生型表达模式。在34例(85%)的反应性尿路积型原型中观察到细胞质CK20免疫反应性,6例(15%)为阴性。此外,35例(88%)的反应性尿路上皮缺点展示了全厚的CD44表达,而5例(12%)局限于尿溶质的基础/帕拉氏层。在39例(98%)CIS中存在强烈和漫射CK20阳性,并且在1例(2%)中检测到斑块状的阳性。无线案例无表达CD44:16例(40%)显示非宝底基础细胞层中的焦点表达; 24例(60%)没有染色。总之,KI-67对反应性尿路上皮类别患者对CI的差异差,并少于经典CK20 / CD44免疫蛋白型。虽然CIS的P53敏感性相对较低(30%),并且作为野生型或阴性的解释可能是挑战的,但在小的情况下可能具有挑战性,而强烈的和弥漫性核反应性是100%的特异性,这些群组中的植物反应性尿路上皮缺点区别。 (c)2020 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号